Rosetta Genomics, NYU Add Neonatal Heart Disorder to miRNA Cancer Alliance

Nov 20, 2007

NEW YORK (GenomeWeb News) — Rosetta Genomics has added congenital neonatal cardiovascular disease to a collaboration with the New York University School of Medicine that was originally created to use miRNA technology to develop cancer diagnostics, the company said today.

Rehovot, Israel-based Rosetta Genomics said the research will screen for specific miRNA biomarkers and signatures that could help diagnose or target congenital heart disease in newborns.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu